I've been following the Myriad Genetics BRCA1 and BRCA2 (breast cancer markers) gene patent case for a while, mainly because Myriad Genetics is located in my "backyard" (Salt Lake City). Yesterday, the US Supreme Court ruling invalidates patent claims to naturally occuring DNA sequences .
This decision invokes a number of different thoughts in my mind, including:
Now there is no longer a monoply on this genetic test in the US, and the test should become more widely available and at a reduced cost (Myriad charges $4,000 !!!) - a relief to women nation-wide How does this ruling... Read more